Drug · DIN 02511045
ABRILADA
SINGLE-DOSE PREFILLED PEN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 24, 2022; first marketed February 24, 2022.
- Drug Identification Number (DIN)
- 02511045
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Adalimumab L04AB04
- Class
- Human
- Record last updated
- August 12, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ADALIMUMAB | 40 MG | 0.8 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 14, 2021: NOC 25020New Drug Submission (NDS)
Other DINs named ABRILADA
- DIN 02511053 · Marketed
- DIN 02511061 · Marketed
- DIN 02511088 · Approved
- DIN 02511096 · Approved